Last Price
7.57
Today's Change
0.00 (0.00%)
Day's Change
0.00 - 0.00
Trading Volume
0
Market Cap
210 Million
Shares Outstanding
27 Million
Avg Volume
253,672
Avg Price (50 Days)
5.08
Avg Price (200 Days)
4.22
PE Ratio
-2.57
EPS
-2.94
Earnings Announcement
07-Aug-2024
Previous Close
6.96
Open
7.05
Day's Range
7.0 - 7.71
Year Range
2.25 - 7.99
Trading Volume
335,197
1 Day Change
8.76%
5 Day Change
2.16%
1 Month Change
55.44%
3 Month Change
79.38%
6 Month Change
180.37%
Ytd Change
84.18%
1 Year Change
7.38%
3 Year Change
-28.38%
5 Year Change
-92.28%
10 Year Change
-99.20%
Max Change
-99.20%
No result.
Sector: Healthcare - Healthcare
Industry: Medical Devices
Description:
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
k6ii
Anyone here see this stock?
2016-09-21 10:41